Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://kalkinemedia.com/uk/news/featured-news/tekcapital-addresses-the-growing-relevance-of-intellectual-property-for-business
We know most of this but this section on Lucyd is news to me
Additionally, Lucyd has exclusively licensed its IP to Innovative Eyewear Inc., which will be manufacturing and marketing Lucyd products globally.
Not sure what the deal is with Eyewear or how big Eyewear are globally but money for nothing. It's either based on royalties or a flat rate licence. Something to chew the cud over
Hi Philbatch - I consider Bellescura as most likely to come in so if it does and no other news has dropped on the other companies I would bail at around 30p. If other news has dropped first on one of the other companies and we are talking about a higher SP bass i'd probably top slice on wait for the Bellescura news. Just my take but will review along the way
Personally it depends on what other news is still expected. If FDA and Guident news has been released I will probably top slice as I feel the others are longer term projects even Salarius, just can't see multi million £ contracts being handed out in the current environment, maybe a buyout although that could be wishful thinking!.
Vusy,
I think you might be getting a little carried away, I would suggest around 25-30p to start but I'm happy to go with £1!
With the FDA approval, this stock could rise close to £1. Remember currently Tek is trading at a big discount. The (NAV) net asset value is 35p and with the FDA, the NAV is going up 3 to 4 fold.
I'd be happy to get any positive news other than a picture of a shelf full of crisps or another patent application. Good sales figures for Lucyd, Guident bought out by Tesla and FDA approval lands. That should move things along nicely.
14:23 I would say 29 to 34p
KR
GS
Charts point to 30p but hard to value traditionally - Obviously if they list we can work it out from there but the FDA approval will come first so very hard to guage. Guident should be releasing news in the non to distant too by all accounts.
Hi all - Serious question to long term holders. Considering TEK's cut in Bellascura (without the buy in option) who would like to share their valuations on FDA approval.
Regards
TC
Hi Steve , the latest position (as I understand it) is anticipated 510k clearance in H2 2020.
If that was achieved it would represent a fantastic result for investors as approval is definitely not fully factored into the share price .
What are you referring to with regard to listing this year ? Was this information pre the delay outlined in June 2020?
Apologies if I have missed something.
510k approval anytime in H2 2020 would be huge for this stock . The listing process should not represent a significant barrier after 510k approval
Totally agree it's risky to be out but if they want to list Belluscura before the year end as they have stated, FDA approval needs to drop in the next few weeks and defo before end of September.
Make no mistake when news drops before year end, this will go through the roof, id rather be on board and ready than not.
For those of you who follow fact and not just wishful thinking and optimism. The FDA are pulling out all the stops to ensure that medical equipment that is in high demand gets tested in an expedited manner. With many new devices being fast tracked through to Emergency Use Approval. There will be no blame apportioned to the FDA on delays to the Belluscura device not being approved if it doesn't happen in the next 6 weeks to fit in with the statements made by the CEO about a Belluscura listing this year. The below is a cut and paste directly from the FDA.
"During the COVID-19 public health emergency (PHE), the FDA has taken many actions to help ensure that patients and health care providers have timely and continued access to high-quality medical devices to respond effectively to the COVID-19 public health emergency. These actions include issuing Emergency Use Authorizations (EUAs) and guidance documents to provide recommendations and help expand the availability and capability for various diagnostic, therapeutic, and protective medical devices in high demand during the COVID-19 public health emergency. The FDA continues to monitor the healthcare landscape and supply chain for resulting shortages, or meaningful disruptions to U.S. supply, of certain medical devices."